 A phase II, observer blind, randomized controlled trial was conducted at Mahidol University in Bangkok, Thailand to assess the safety and immunogenicity of Bionetaceous Acellular Pertussis, AP, vaccine formulated alone or in combination with tetanus and diphtheria toxoids, TDAP. The study enrolled 60 healthy adult volunteers aged 18 to 35 years old, who were randomized to receive one dose of either Bionet's AP or tetanus toxoid-reduced diphtheria toxoidacellular Pertussis, TDAP, vaccine, or the TDAP Acell registered trademark symbol vaccine. Safety follow-up was performed for one month, and immunogenicity was assessed at baseline, at 7 days and 28 days after vaccination. The results showed that Bionet's AP vaccine elicited significantly higher immune responses to PT and FHA compared to Adacelle registered trademark symbol, while the antipionigg, antotetanus and antideftheria GMTs at one month after immunization were comparable in all vaccine groups. The study concluded that Bionet's AP and TDAP vaccines showed a similar tolerability and safety profile to Adacelle registered trademark symbol. This article was authored by Chukiatsyrivy Chayikul, Pornthep Chantavanich, Kriyingsap Limkitikul, and others. We are article.tv, links in the description below.